Dianthus Therapeutics Inc...

NASDAQ: DNTH · Real-Time Price · USD
20.71
0.46 (2.27%)
At close: Aug 15, 2025, 3:59 PM
20.74
0.14%
After-hours: Aug 15, 2025, 04:10 PM EDT

Dianthus Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
193K 1.16M 1.33M 2.17M 1.86M 874K 457K 924K 969K 476K 1.18M 1.17M n/a n/a n/a n/a n/a n/a
Cost of Revenue
99K 133K 78K 116K 111K 107K 103K 19K n/a 1.21M 1.23M 1.21M 1.2M 1.21M 535K 532K 479K n/a
Gross Profit
94K 1.16M 1.33M 2.17M 1.86M 874K 457K 905K 969K -731K -53K -38K -1.2M -1.21M -535K -532K -479K n/a
Operating Income
-34.93M -33.18M -31.92M -29.9M -22.2M -17.84M -12.96M -15.76M -5.46M -14.13M -10.69M -8.25M -18.08M -23.83M -20.14M -18.25M -17.61M -18.7M
Interest Income
3.4M 3.79M 3.99M 4.45M 4.71M 4.22M 2.44M 1.03M 687K 606K 640K 416K 812K 884K 848K 818K n/a 1.21M
Pretax Income
-31.63M -29.51M -28.44M -25.17M -17.61M -13.75M -10.56M -14.76M -3.28M -29.17M -10.12M -7.78M -17.27M -22.95M -19.29M -17.43M -16.93M -17.49M
Net Income
-31.63M -29.51M -28.44M -25.17M -17.61M -13.75M -10.56M -14.76M -3.28M -29.17M -10.12M -7.78M -17.27M -22.95M -19.29M -17.43M -16.93M -17.49M
Selling & General & Admin
8.87M 7.34M 6.83M 6.53M 6M 5.64M 4.63M 8.72M 2.49M 6.13M 2.04M 2.21M 6.48M 7.29M 7.03M 7.45M 6.48M 6.97M
Research & Development
26.25M 27M 26.41M 25.54M 18.07M 13.08M 8.78M 7.96M 139K 6.79M 9.83M 7.22M 10.41M 16.55M 13.11M 10.79M 11.13M 11.73M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a -3K -43K -2K n/a n/a n/a n/a n/a n/a
Operating Expenses
35.12M 34.34M 33.24M 32.07M 24.07M 18.72M 13.41M 16.68M 12.74M 12.92M 11.87M 9.43M 16.89M 23.83M 20.14M 18.25M 17.61M 18.7M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.19M 812K 884K 848K 818K 682K 1.21M
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a 3.82M n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
35.12M 34.34M 33.24M 32.07M 24.07M 18.72M 13.41M 16.68M 12.74M 14.13M 11.87M 9.43M 18.08M 23.83M 20.14M 18.25M 17.61M 18.7M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a 179K 1.17M n/a n/a n/a n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
35.82M 35.79M 35.03M 34.24M 34.23M 25.67M 4.53M 3.91M 3.79M 3.79M 3.79M 3.7M 3.68M 3.67M 3.67M 3.66M 3.36M 3.04M
Shares Outstanding (Diluted)
35.82M 35.79M 35.03M 34.24M 34.23M 25.67M 4.53M 3.91M 3.79M 3.79M 3.79M 3.7M 3.68M 3.67M 3.67M 3.66M 3.36M 3.04M
EPS (Basic)
-0.88 -0.82 -0.81 -0.74 -0.51 -0.54 -2.33 -3.78 -0.87 -7.7 -2.67 -2.1 -4.7 -6.24 -5.25 -4.76 -5.04 -5.76
EPS (Diluted)
-0.88 -0.82 -0.81 -0.74 -0.51 -0.54 -2.33 -3.78 -0.87 -7.7 -2.67 -2.1 -4.7 -6.24 -5.25 -4.76 -5.04 -5.76
EBITDA
-34.93M -33.04M -31.84M -29.78M -22.09M -17.74M -12.85M -15.67M -11.69M -7.6M -10.64M -8.31M -16.07M -21.74M -18.76M -16.89M -16.45M -17.02M
EBIT
-31.63M -33.18M -31.92M -29.9M -22.2M -17.84M -12.96M -15.76M -11.78M -7.68M -10.69M -8.25M -17.27M -22.95M -19.29M -17.43M -16.93M -17.49M
Depreciation & Amortization
99K 133K 78K 116K 111K 107K 103K 87K 84K 1.21M 1.23M 1.21M 1.2M 1.21M 535K 532K 479K 474K